

FORM 51-102F3

MATERIAL CHANGE REPORT

1. Name and Address of Company

Rapid Dose Therapeutics Corp. (the "**Company**")

1121 Walkers Line, Unit 3 Burlington, Ontario L7N 2G4

2. Date of Material Change

June 18, 2021 and June 29, 2021.

3. News Release

News releases dated June 18, 2021 and June 29, 2021 were disseminated through the facilities of EIN Presswire and subsequently filed on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.

4. Summary of Material Change

On June 18, 2021, the Company announced that the filing of its audited annual financial statements, management's discussion and analysis, and related CEO and CFO certifications for the financial year ended February 28, 2021 will be delayed beyond the filing deadline of June 28, 2021 and that the Company had made an application to the Ontario Securities Commission (the "**OSC**") for a management cease trade order (the "**MCTO**").

On June 29, 2021, the Company announced that its principal regulator, the OSC granted a MCTO, under National Policy 12-203 - *Management Cease Trade Orders* ("**NP 12-203**").

5. Full Description of Material Change

5.1 Full Description of Material Change

On June 18, 2021, the Company announced the following:

"Rapid Dose Therapeutics Corp. (the "Company") (CSE: DOSE) announces that the filing of its annual financial statements for the year ended February 28, 2021, including related management discussion and analysis, and CEO and CFO certifications (collectively, the "Annual Financial Filings") will be delayed beyond the filing deadline of June 28, 2021 (the "Filing Deadline"). The Annual Financial Filings will not be filed by the Filing Deadline due principally to delays resulting from the work associated with the audit of the Issuer's amalgamation with 2544737 Ontario Limited, operating as Consolidated Craft Brands, announced by the Issuer on March 8, 2021, and delays resulting from COVID 19 operating protocols observed by the Company and its auditor.

The Company is working on the steps required to complete the Annual Financial Filings and expects to be able to file the Annual Financial Filings by August 31, 2021. The Company will provide updates as further information relating to the Annual Financial Filings becomes available.

The Company has applied to the applicable securities regulatory authorities for a management cease trade order ("MCTO") to be imposed against the Chief Executive Officer and Chief Financial Officer of the

Company precluding them from trading securities of the Company until the Annual Financial Filings are filed. The MCTO would not affect the ability of shareholders who are not insiders of the Company to trade their securities. There is no certainty that the MCTO will be granted. If the MCTO is not granted, the applicable securities regulatory authorities could issue a general cease trade order against the Company for failure to file the Annual Filings by the Filing Deadline.

Until the Annual Financial Filings are filed, the Company intends to satisfy the provisions of the alternative information guidelines under National Policy 12-203 - Management Cease Trade Orders by issuing biweekly default status reports. The Company confirms that there is no other material information relating to its affairs that has not been generally disclosed.”

On June 29, 2021, the Company announced the following:

“Rapid Dose Therapeutics Corp. (the “Company”) (CSE: DOSE) announces that, further to its news release dated June 18, 2021, the Company’s principal regulator, the Ontario Securities Commission (the “OSC”) granted a management cease trade order (the “MCTO”) on June 29, 2021, under National Policy 12-203 - *Management Cease Trade Orders* (“NP 12-203”). Pursuant to the MCTO, the Company’s Chief Executive Officer and Chief Financial Officer may not trade in securities of the Company until such time as the Company files its annual audited financial statements, annual management's discussion and analysis and related certifications for the year ended February 28, 2021 (collectively, the "Annual Financial Documents"), and the Executive Director of the OSC revokes the MCTO. The MCTO does not affect the ability of other shareholders to trade their securities.

As previously announced, the delay in the completion of the Annual Financial Documents is due principally to delays resulting from the work associated with the audit of the Company’s amalgamation with 2544737 Ontario Limited, operating as Consolidated Craft Brands, announced by the Company on March 8, 2021, and delays resulting from COVID 19 operating protocols observed by the Company and its auditor. The Company is working on the steps required to complete the Annual Financial Documents and expects to be able to file the Annual Financial Documents by August 30, 2021. The Company will provide updates as further information relating to the Annual Financial Documents becomes available.

Bi-Weekly Status Report

The Company confirms that since the June 18, 2021 date of announcing the delay in completion of the Annual Financial Documents (the "Default Notice"): (i) there has been no material change to the information set out in the Default Notice that has not been generally disclosed; (ii) there has been no failure by the Company in fulfilling its stated intentions with respect to satisfying the provisions of the alternative information guidelines set out in NP 12-203; (iii) there has not been any other specified default by the Company under NP 12-203; and (iv) there is no other material information concerning the affairs of the Company that has not been generally disclosed.

Until the Annual Financial Documents have been filed, the Company intends to continue to satisfy the provisions of the alternative information guidelines specified in NP 12-203 by issuing bi-weekly default status reports in the form of further press releases for so long as the Company remains in default of the financial statement filing requirement. In the event that the Company does not file the Annual Financial Documents in a timely manner, the Canadian Securities Regulatory Authorities may impose an issuer cease trade order on the outstanding securities of the Company.”

5.2 Disclosure for Restructuring Transaction

Not applicable

6. Disclosure for Restructuring Transaction

Not applicable.

7. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

8. Omitted Information

Not applicable.

9. Executive Officer

For additional information please contact Mark Upsdell, Chief Executive Officer of the Company at (416) 477-1052; mupsdell@rapid-dose.com.

10. Date of Report

June 30, 2021.